10-Q: Pasithea Therapeutics Q3 2026: Rising R&D Costs, Cash Burn Continues

Pasithea Therapeutics reported a net loss of $6.58 million for Q3 2026, with research and development expenses surging by 228.3% year-over-year, while cash reserves decreased significantly.

Summary

• Pasithea Therapeutics reported a net loss of $6,579,393 for the third quarter ended September 30, 2026, compared to a net loss of $3,037,420 for the same period in 2025.
• Research and development expenses significantly increased by 228.3% to $4,457,107 in Q3 2026 from $1,357,793 in Q3 2025.
• General and administrative expenses also rose by 43.4% to $2,512,575 in Q3 2026 compared to $1,752,262 in Q3 2025.
• The company's cash and cash equivalents decreased to $41.2 million as of September 30, 2026, from $55.2 million as of December 31, 2025.
• The company continues to rely on equity and/or debt securities for funding to continue its development plans and operations.
• The company's lead product candidate, PAS-004, is in Phase 1/1b clinical trials for NF1-associated plexiform neurofibromas and advanced tumors.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant operating losses, increasing R&D expenses, and a continued reliance on external financing, despite a substantial cash balance.

Positives

• The company has a substantial cash balance of $41.2 million as of September 30, 2026, which management believes is sufficient to fund operations for at least the next twelve months.
• The FDA cleared the company's Investigational New Drug (IND) application for a Phase 2 clinical trial for PAS-004 in patients with NF1-associated cutaneous neurofibromas in November 2026.
• The company has a clear focus on developing PAS-004 for specific indications within neurofibromatosis type 1 (NF1).

Negatives

• The company reported a net loss of $6,579,393 for Q3 2026, a significant increase from $3,037,420 in Q3 2025.
• Research and development expenses more than tripled, increasing by 228.3% to $4,457,107 in Q3 2026.
• General and administrative expenses increased by 43.4% to $2,512,575 in Q3 2026.
• Cash and cash equivalents decreased by approximately $13.9 million during the first nine months of 2026.
• The company has an accumulated deficit of $84.7 million as of September 30, 2026.
• The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities.

Risks

• The company expects to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through development and clinical trials.
• Adequate funding may not be available on acceptable terms, or at all, which could lead to significant delays, scaling back, or discontinuation of development.
• The development and commercialization of pharmaceutical products involve numerous risks and uncertainties, making it impossible to estimate exact capital requirements.
• The company's ability to generate product revenue depends on the successful development, regulatory approval, and eventual commercialization of its product candidates.
• The company is subject to the risks and uncertainties associated with clinical trials, including the timing, progress, results, and costs.
• Inflation is expected to continue to have a negative impact throughout 2026, with uncertainty regarding the company's ability to offset these pressures.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates. Future funding will be dependent on the sale of equity and/or debt securities. Management believes current cash reserves are sufficient for at least the next twelve months, but significant additional funds will be required for clinical trials and other development activities.

Management Comments

• Management considered whether or not there are conditions or events, in the aggregate, that raise substantial doubt about the entitys ability to continue as a going concern, and concluded that there are none as it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these condensed consolidated financial statements.
• We expect general and administrative expenses to continue to increase in fiscal year 2026 as compared to fiscal year 2025 primarily due to a ramp up in operational activity, public company and corporate communications expenses, and non-cash stock-based compensation, partially offset by a decrease in impairment expenses.
• We expect research and development expenses to continue to increase in fiscal year 2026 as compared to fiscal year 2025 primarily due to an increase in clinical trial and regulatory expenses related to our ongoing clinical trials for PAS-004 and preparation for future clinical trials, an increase in CMC costs related to PAS-004 drug product and drug supply for our clinical trials, as well as the development of a liquid formation of PAS-004, the ongoing non-clinical absorption, distribution, metabolism and excretion (ADME) studies, and non-clinical developmental and reproductive toxicology studies, the ongoing clinical human ADME studies, and an increase in personnel costs related to new workforce hires to support our research and development activities.

Industry Context

StockSavvy.ai notes that Pasithea Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The significant increase in R&D spending is typical for companies advancing drug candidates through clinical trials, but the substantial net loss and reliance on future financing highlight the inherent risks in this industry. The company's focus on RASopathies and MAPK pathway-driven tumors places it in a niche within oncology drug development.

Comparison to Industry Standards

• Clinical-stage biotechnology companies often experience significant operating losses and negative cash flows from operations as they invest heavily in research and development, which is consistent with Pasithea's financial profile.
• The increasing R&D expenditure as a percentage of total expenses is a common trend for companies progressing through Phase 1 and Phase 2 trials, aiming to validate drug efficacy and safety.
• The reliance on equity financing (public offerings, ATM sales) is a standard practice for biotechnology firms lacking product revenue to fund their extensive development pipelines.

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely to it, are believed to have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Related Party Transactions

• Consulting agreement with Prof. Lawrence Steinman, providing services related to clinical and commercial development of product candidates. Compensation was reduced to $1.00 per quarter effective October 1, 2025.

Stakeholder Impact

• Shareholders face continued dilution risk due to the company's reliance on equity financing to fund operations and development.
• Employees may face uncertainty regarding job security if funding is not secured, impacting the company's ability to execute its development plans.
• Creditors and suppliers may face payment risks if the company cannot secure sufficient funding to meet its obligations.

Next Steps

• Continue Phase 1/1b open-label, dose escalation trial of PAS-004 in adult patients with NF1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
• Initiate a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with NF1-associated cutaneous neurofibromas, following FDA IND clearance.
• Continue discovery stage research for PAS-001 for the treatment of schizophrenia.
• Seek additional working capital funding through the sale of equity and/or debt securities.

Key Dates

Recommendation

Pasithea Therapeutics presents a mixed picture. While the company has a substantial cash runway and positive clinical trial developments (FDA IND clearance for Phase 2), the significant increase in operating losses and R&D expenses, coupled with the ongoing need for external financing, introduces considerable risk. The 'hold' recommendation reflects a cautious approach, balancing the potential of its lead candidate against the financial uncertainties and execution risks inherent in clinical-stage biotech.

Keywords

biotechnology, clinical-stage, drug development, PAS-004, MEK inhibitor, neurofibromatosis, NF1, oncology